Executive record
Christopher A. Viehbacher
Public governance roles and source-backed Claims for this individual.
More
Alpha ID: alpha:person:christopher-a-viehbacherVersion: public-0As of: 2026-10-03
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Mr. Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies. He brings a keen understanding of the complexities involved in running a multibillion-dollar global pharmaceutical business as well as an appreciation for the value of innovation. He previously served as Global CEO of Sanofi S.A.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Claims
Executive career
- 2026 to end not publishedExecutive title: President, Chief Executive Officer · Organization not publishedBIIB 10-K executive officers
- Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedBIIB DEF 14A director slate
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Biogen Inc. director board source
sec filing · Source published: Apr 28, 2026 · Retrieved: May 3, 2026
Supports 2 claims
- Board independence: Not independent (executive director) · Claim reviewed: May 3, 2026
- Board membership: Serves on the board of Biogen Inc. · Claim reviewed: May 3, 2026
BIIB 10-K executive officers
sec filing · Source published: Feb 6, 2026 · Retrieved: May 13, 2026
Supports 6 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Executive company: Executive at Biogen Inc. · Claim reviewed: May 15, 2026
- Executive title: Executive title: President, Chief Executive Officer · Claim reviewed: May 13, 2026
- Other Company Role: Christopher A. Viehbacher is also linked to Braveheart Bio, Inc. as Chair of the Board of Directors. · Claim reviewed: May 13, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026
BIIB DEF 14A director slate
sec filing · Source published: Apr 28, 2025 · Retrieved: May 15, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Board role: Board role: Director · Claim reviewed: May 15, 2026
- Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
- Executive company: Executive at Biogen Inc. · Claim reviewed: May 15, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026
BIIB executive roster source
sec filing · Source published: Date unavailable · Retrieved: May 3, 2026
Supports 5 claims
- AI expertise: AI expertise reported in filings · Claim reviewed: May 3, 2026
- AI governance relevance: AI governance relevance reported from role and filings · Claim reviewed: May 3, 2026
- Executive company: Executive at Biogen Inc. · Claim reviewed: May 15, 2026
- Executive function: Enterprise Leadership (CEO) · Claim reviewed: May 3, 2026
- Executive title: Executive title: President, Chief Executive Officer · Claim reviewed: May 13, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-03
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- published
- Background screening
- out of scope

